{
    "nctId": "NCT03177811",
    "officialTitle": "Effect of Acetazolamide on Postural Control in Patients With Chronic Obstructive Pulmonary Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial",
    "inclusionCriteria": "* Male and female patients, age 18-75 yrs.\n* COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 \u226592% at 750 m.\n* Born, raised and currently living at low altitude (\\<800m).\n* Written informed consent.\n* Must have minimum age of 18 Years\n* Must have maximum age of 75 Years",
    "exclusionCriteria": "* COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC \\<0.7, FEV1 \\<40% predicted, oxygen saturation on room air \\<92% at 750 m).\n* Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.\n* Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (\\>20 cigarettes per day)\n* Known renal failure or allergy to acetazolamide and other sulfonamides"
}